Literature DB >> 12571262

Pharmacogenomics--drug disposition, drug targets, and side effects.

William E Evans1, Howard L McLeod.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 12571262     DOI: 10.1056/NEJMra020526

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  355 in total

Review 1.  Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.

Authors:  Haiyan Li; Kathleen Butler; Li Yang; Zhenghua Yang; Renli Teng
Journal:  Clin Drug Investig       Date:  2012-02-01       Impact factor: 2.859

3.  Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

Authors:  Howard L McLeod; Daniel J Sargent; Sharon Marsh; Erin M Green; Cristi R King; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Stephen N Thibodeau; Axel Grothey; Roscoe F Morton; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

4.  Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China.

Authors:  Yong Song; Wujun Xue; Puxun Tian; Xiaoming Ding; Xiaoming Pan; Hang Yan; Jun Hou; Xinshun Feng; Heli Xiang; Xiaohui Tian; Gaoping Qin; Xiaohu Fan
Journal:  Eur J Clin Pharmacol       Date:  2011-01-29       Impact factor: 2.953

5.  The genomification of medicine.

Authors: 
Journal:  CMAJ       Date:  2003-04-15       Impact factor: 8.262

Review 6.  The role of cost-effectiveness analysis in the era of pharmacogenomics.

Authors:  Christopher R Flowers; David Veenstra
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

7.  Large-scale single-nucleotide polymorphism (SNP) and haplotype analyses, using dense SNP Maps, of 199 drug-related genes in 752 subjects: the analysis of the association between uncommon SNPs within haplotype blocks and the haplotypes constructed with haplotype-tagging SNPs.

Authors:  Naoyuki Kamatani; Akihiro Sekine; Takuya Kitamoto; Aritoshi Iida; Susumu Saito; Akifumi Kogame; Eisuke Inoue; Manabu Kawamoto; Masayoshi Harigai; Yusuke Nakamura
Journal:  Am J Hum Genet       Date:  2004-06-16       Impact factor: 11.025

Review 8.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 9.  Pharmacogenetics of the beta 2-adrenergic receptor gene.

Authors:  Victor E Ortega; Gregory A Hawkins; Stephen P Peters; Eugene R Bleecker
Journal:  Immunol Allergy Clin North Am       Date:  2007-11       Impact factor: 3.479

10.  Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.